## **Trustees’ Annual Report for the period**
## **From 25/7/2022 Period start date To 24/7/2023 Period end date**
**Charity name:** ASSOCIATION FOR THE GLOBAL ADVANCEMENT OF ENT SURGERY AND HEAD AND NECK CANCER RESEARCH
## **Charity registration number:** 1165453
## **Objectives and Activities**
||SORP reference||
|---|---|---|
|Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|The advancement of health and relief of
sickness in the field of ear, nose and
throat/head and neck surgery and head
and neck disorders across the world in
particular but not exclusively by:
· Supporting the provision of awareness
and screening programmes
· Supporting cancer research by the
provision of grants
(AGA-ENT Charity Governing document -
version 1.1-21/1/2016)|
|Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.|Para 1.17 and
1.19|· Supporting the provision of awareness
and screening programmes
· Supporting cancer research by the
provision of grants and support for UK and
international research|
|Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit|Para 1.18|Yes, the trustees have had regard.|
## **Additional information (optional)** You may choose to include further statements where relevant about:
SORP reference N/A Para 1.38 Policy on grant making N/A Para 1.38 Policy on social investment including program related investment
|Contribution made by
volunteers|Para 1.38|Minor contributions, e.g. help with social
media.|
|---|---|---|
|Other||N/A|
## **Achievements and Performance**
||SORP reference||
|---|---|---|
|Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|Our work has unfortunately been affected
by the pandemic, but we had continued the
fundraising and were able to have our
programme fully up and running again in
2023 again.
We have supported fellows with grants in
the past and the travel fellowships which
had been awarded will now be utilised in
line with the aims and objectives of the
charity in 2023. Moreover, we have
awarded two more fellowships for 2023
with fellows travelling to Uganda and
Tanzania.
After our BICRAA app (www.bicraa.org)
had been successfully tested in India
(n=1049), showing that around 30% chew
betel nut (we would like to thank Prof.
Kelkar and Dr. Pethe from the Deenanath
Mangeshkar Hospital, Pune, for their
invaluable support), the app has continued
to help raise the awareness of the risks of
betel nut chewing and we have recently
completed a study in Taiwan (n=>1000).
With regard to our work in Indonesia, we
have continued to closely work with our
partners at the Dr. Sardjito Hospital/Gadjah
Mada University in Yogyakarta, Indonesia,
and one of the trustees, Mr. Matt Lechner,
travelled there in September 2022 to
support the local Nasopharyngeal Cancer
(NPC) awareness and early detection
programme and to support research and
publications of results. The company KARL
STORZ has continued to support our
programme.|
## **Additional information (optional)** You may choose to include further statements where relevant about:
|Achievements against
objectives set|Para 1.41|As above. Taking the above work into
account AGA-ENT has made contributions
to the advancement of health and relief of
sickness in the field of ear, nose and
throat/head and neck surgeryand head|
|---|---|---|
|||and neck disorders in low and middle
income countries.|
|---|---|---|
|Performance of fundraising
activities against objectives
set|Para 1.41|Good progress. Substantive funding will be
sought once the preliminary data are
published.|
|Investment performance
against objectives|Para 1.41|N/A|
|Other||N/A|
## **Financial Review**
|**Financial Review**|||
|---|---|---|
|Review of the charity’s
financial position at the end
of the period|Para 1.21|24/7/2023|
|Statement explaining the
policy for holding reserves
stating why they are held|Para 1.22|Year on year the charity hopes to increase
the reserves to be in line with 2 years
possible commitments|
|Amount of reserves held|Para 1.22|£1000|
|Reasons for holding zero
reserves|Para 1.22|N/A|
|Details of fund materially in
deficit|Para 1.24|N/A|
|Explanation of any
uncertainties about the
charity continuing as a going
concern|Para 1.23|N/A|
|Details of fund materially in
deficit
Para 1.24
Explanation of any
uncertainties about the
charity continuing as a going
concern
Para 1.23|Details of fund materially in
deficit
Para 1.24
Explanation of any
uncertainties about the
charity continuing as a going
concern
Para 1.23|N/A
N/A|
|---|---|---|
|**Additional information (optional)**
You may choose to include further statements||where relevant about:|
|The charity’s principal
sources of funds (including
any fundraising)|Para 1.47|Donations by private donors and donated
equipment.|
|Investment policy and
objectives including any
social investment policy
adopted|Para 1.46|N/A|
|A description of the principal
risks facing the charity|Para 1.46|At present funds are sufficient to achieve
the aims set, but more funding needs to be
sought to continue to expand our work.
Ensuring the ongoing income is the most
important risk we manage.|
|Other||N/A|
## **Structure, Governance and Management**
|Description of charity’s
trusts:|||
|---|---|---|
|Type of governing document
(trust deed, royal charter)|Para 1.25|Constitution of the Association for the
Global Advancement of ENT Surgery and
Head and Neck Cancer Research (AGA-
ENT), a Charitable Incorporated
Organisation with voting members other
than its charity trustees
Date of constitution (last amended):
21/01/2016 (AGA-ENT Charity Governing
document - version 1.1 - 21/1/2016)|
|How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|Charitable Incorporated Organisation|
|Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|The current trustees volunteered to take on
these roles with the support of all founding
members and fulfil these roles in line with
the duties outlined in the AGA-ENT Charity
Governing document - version 1.1 -
21/1/2016|
## **Additional information (optional)** You may choose to include further statements where relevant about:
|Policies and procedures
adopted for the induction
and training of trustees|Para 1.51|All duties outlined in the AGA-ENT Charity
Governing document - version 1.1 -
21/1/2016 and discussed during regular
Trustees’ meetings.|
|---|---|---|
|The charity’s organisational
structure and any wider
network with which the
charity works|Para 1.51|Charitable Incorporated Organisation with
voting members other than its charity
trustees|
|Relationship with any
related parties|Para 1.51|Collaborators and partners globally who
help to achieve the outlined objectives,
usually within the network of Founding
Members.|
|Other||N/A|
## **Reference and Administrative details**
|Charity name|Association for the Global Advancement of ENT Surgery and
Head and Neck Cancer Research (AGA-ENT)|
|---|---|
|Other name the charity uses|AGA-ENT|
|Registered charity number|1165453|
|Charity’s principal address|Association for the Global Advancement of ENT Surgery and
Head and Neck Cancer Research (AGA-ENT), Beacon
House, 113 Kingsway, London, WC2B 6PP|
|---|---|
|||
## **Names of the charity trustees who manage the charity**
|1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**
**year**|**Name of person (or body) entitled**
**to appoint trustee(if any)**|
|---|---|---|---|---|
||Paul O’Flynn||5/2/2016 – current date|Membershipbody|
||Matt Lechner||5/2/2016 – current date|Membershipbody|
||Valerie J. Lund||5/2/2016 – current date|Membershipbody|
||Francis M. Vaz||5/2/2016 – current date|Membershipbody|
||Tim Tang||5/2/2016 - 4/6/2017|Membershipbody|
||TerryM. Jones||6/6/2023 – current data|Membershipbody|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
## – Corporate trustees names of the directors at the date the report was approved
**Director name** N/A
Name of trustees holding title to property belonging to the charity
|**Trustee name**|**Dates acted if not for whole year**||
|---|---|---|
|N/A|||
||||
||||
||||
||||
||||
## **Funds held as custodian trustees on behalf of others**
Description of the assets None held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets
## **Additional information (optional)**
## **Names and addresses of advisers (Optional information)**
|**Additional information (optional)**
**Names and addresses of advisers (Optional information)**|**Additional information (optional)**
**Names and addresses of advisers (Optional information)**|**Additional information (optional)**
**Names and addresses of advisers (Optional information)**|
|---|---|---|
|**Type of**
**adviser**
**Name**
**Address**|||
|N/A|||
||||
||||
||||
|**Name of chief executive or names of senior staff members (Optional information)**|||
|N/A|||
N/A
## **Exemptions from disclosure**
Reason for non-disclosure of key personnel details
The charity is too small still to employ personnel
## **Other optional information**
N/A
## **Declarations**
**The trustees declare that they have approved the trustees’ report above.**
**Signed on behalf of the charity’s trustees**
**Signature(s) Full name(s)** Mr. Matt Lechner **Position (eg Secretary,** Trustee **Chair, etc) Date** 13/08/2023
Prof. Valerie J. Lund
||**Association for the Global Advancement of ENT Surgery**
**and Head and Neck Cancer Research**|**Association for the Global Advancement of ENT Surgery**
**and Head and Neck Cancer Research**|**Association for the Global Advancement of ENT Surgery**
**and Head and Neck Cancer Research**|**1165453**|**1165453**|**CC16a**|
|---|---|---|---|---|---|---|
||**For the period**
**from**|25/07/2022|**To**||24/07/2023||
||||||||
|**Section A Receipts and payments**|||||||
|**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**1,743**
**-**
**5**
**-**
**-**
**-**
**-**
**1,748**
**-**
**-**
**-**
**1,748**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**||**Total funds**
**to the nearest £**
**1,743**
**-**
**-**
**5**
**-**
**-**
**-**
**-**
**1,748**
**-**
**-**
**-**
**1,748**|**Last year**
**to the nearest £**|
|Donations|**1,743**|||||**757**|
|FellowshipFunding||||||**3,000**|
||**-**|||||**-**|
|Bank interest|**5**|||||**2**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_
_AR)_|**1,748**|||||**3,759**|
||||||||
|**A2 Asset and investment sales,**
**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|**_Sub total_**|**-**|||||**-**|
|**_Total receipts_ **|||||||
||**1,748**|**-**|**-**||**1,748**|**3,759**|
## **A3 Payments**
|**A3 Payments**|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Fundraisingcosts|**134**||**-**||||**-**|||**134**||**-**|
|Web hosting|**40**||**-**||||**-**|||**40**||**34**|
|Research Grant|**5,000**||**-**||||**-**|||**5,000**||**3,096**|
|FundingApplication|**-**||**-**||||**-**|||**-**||**500**|
|Office costs|**213**||**-**||||**-**|||**213**||**19**|
|Travel expenses|**732**|||||||||**732**||**-**|
|Legal andprofessional fees|**690**||**-**||||**-**|||**690**||**1,500**|
||**-**||**-**||||**-**|||**-**||**-**|
||**-**||**-**||||**-**|||**-**||**-**|
|**_Sub total_ **|**6,809**||**-**||||**-**|||**6,809**||**5,149**|
||||||||||||||
|**A4 Asset and investment**|||||||||||||
|**purchases, (see table)**|||||||||||||
||**-**|||**-**||||**-**||**-**|||
||**-**|||**-**||||**-**||**-**|||
|**_Sub total_ **|**-**|||**-**||||**-**||**-**||**-**|
||||||||||||||
|**_Total payments_**|**6,809**|||**-**||||**-**||**6,809**||**5,149**|
|**_Net of receipts/(payments)_**|**- 5,062**|||**-**||||**-**||**- 5,062**||**- 1,390**|
|**A5 Transfers between funds**|**-**|||**-**||**-**||||**-**||**-**|
|**A6 Cash funds last year end**|**9,186**|||**-**||**-**||||**9,186**||**10,576**|
|**_Cash funds this year end_**|**4,124**|||**-**||||**-**||**4,124**||**9,186**|
1
## **Section B Statement of assets and liabilities at the end of the period**
|**Categories**
Signed by one or two trustees on behalf
of all the trustees
**Details**
**B1 Cash funds**
Bank accounts
**Details**
**B2 Other monetary assets**
**_Total cash funds_**
(agree balances with receipts and payments
account(s))
**Details**
**B3 Investment assets**
**Details**
**B4 Assets retained for the**
**charity’s own use**
**B5 Liabilities**
Signature
**Details**
Matt Lechner|**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**4,124**
**-**
**-**
**-**
**-**
**-**
**4,124**
**-**
OK
OK
**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**liability relates**
**Amount due**
**(optional)**
**-**
**-**
**-**
**-**
Print Name
**M Lechner**|**Endowment**
**funds**
**to nearest £**|
|---|---|---|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||OK|
|||**Endowment**
**funds**
**to nearest £**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**Current value**
**(optional)**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**Current value**
**(optional)**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**-**|
|||**When due**
**(optional)**|
||||
||||
||||
||||
||||
||||
|||Date of
approval|
||**M Lechner**|Oct 13, 2023|
2
## Matt Lechner **Signature:**
Matt Lechner (Oct 13, 2023 09:23 GMT+1)
**Email:** dr.matt.lechner@gmail.com
## AGA-ENT - CC16a - Accounts - y.e 24.07.23agreement draft
## Final Audit Report
## 2023-10-13
Created: 2023-10-12 By: Michelle Cox (michelle@kershen-fairfax.com) Status: Signed Transaction ID: CBJCHBCAABAA6YM3vQjFuK73cMfBSMrbajQhzxzsAeJZ
## "AGA-ENT - CC16a - Accounts - y.e 24.07.23-agreement draft" History
Document created by Michelle Cox (michelle@kershen-fairfax.com)
2023-10-12 - 9:21:39 AM GMT
Document emailed to Matt Lechner (dr.matt.lechner@gmail.com) for signature
2023-10-12 - 9:24:29 AM GMT
Email viewed by Matt Lechner (dr.matt.lechner@gmail.com)
2023-10-12 - 9:38:41 AM GMT
Document e-signed by Matt Lechner (dr.matt.lechner@gmail.com)
Signature Date: 2023-10-13 - 8:23:19 AM GMT - Time Source: server
## Agreement completed.
2023-10-13 - 8:23:19 AM GMT